39 results
Page 2 of 2
8-K
EX-99.1
fjuj nd8py
3 Mar 22
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights
4:36pm
8-K
EX-99.1
towhwisywjvvgz8urz3w
15 Nov 21
Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights
4:21pm
8-K
EX-99.1
yfv1hjv
9 Nov 21
Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501
4:49pm
8-K
EX-99.1
szm3jsaryi8v
29 Sep 21
Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors
12:00am
8-K
EX-99.1
56dc v13g86cnb
16 Aug 21
Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights
4:19pm
8-K
EX-99.1
q3nolmexb1jc3 lje9f0
14 Jun 21
Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH
4:40pm
10-Q
dcgl67q leob5k1m33t
14 May 21
Quarterly report
4:59pm
8-K
EX-99.1
vy09mcw3z45e4 39
13 May 21
Terns Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:17pm
10-K
1p3r 9325mic
30 Mar 21
Annual report
5:21pm
8-K
EX-99.1
cetacb21cy3zt
30 Mar 21
Terns Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
5:04pm
424B4
fuwhwb6os3cscqyof3f
8 Feb 21
Prospectus supplement with pricing info
4:01pm
S-1/A
poi98
1 Feb 21
IPO registration (amended)
7:05am
S-1/A
EX-1.1
b58nh02ux71tq
1 Feb 21
IPO registration (amended)
7:05am
S-1
ti8gh0jrj 77kv
15 Jan 21
IPO registration
5:22pm
DRS/A
7thin1718duva1 3b
16 Dec 20
Draft registration statement (amended)
12:00am
DRS
hkz13jma pr9k
10 Nov 20
Draft registration statement
12:00am